TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

BioPhy Introduces Innovative AI Platform Poised to Transform the Trillion-Dollar Drug Development Market

Wednesday, November 08, 2023

BioPhy recently unveiled its innovative AI operating system, with the aim of transforming the process of identifying and developing promising drug candidates. This platform seamlessly integrates scientific, clinical, and regulatory insights with a unique operational assessment model, streamlining capital allocation and expediting the drug development timeline.

In extensive live testing over the past 27 months, the technology exhibited an impressive 80% accuracy in predicting the outcomes of over 1,500 clinical trials. This level of accuracy holds the potential to result in substantial cost savings for pharmaceutical companies in clinical development. BioPhy's generative AI system supports critical functions within drug development, including clinical operations, regulatory affairs, and quality assurance.

The company is currently engaged in pilot and commercial agreements with several major pharmaceutical companies and has secured $4.5 million in funding from investors, including Chelsea Clinton and Caroline Kassie's Metrodora Ventures, Audere Capital, TRCM, and industry figure Jeff Marrazzo, co-founder of Spark Therapeutics (recently acquired by Roche for nearly $5 billion). BioPhy was co-founded by Dr. Dave Latshaw II, an accomplished computational biomolecular and chemical engineer who previously led AI deployment initiatives at Johnson & Johnson's Advanced Technologies Center of Excellence, resulting in significant cost reduction and increased reliability.

BioPhy, highlighted the importance of AI in addressing the inefficiencies that plague drug development, resulting in wasted resources and delays in delivering therapies to patients. BioPhy's platform aims to harness the power of predictive and generative AI to enhance the chances of clinical success, optimize capital efficiency, and reduce development timelines for pharmaceutical companies and government agencies.

BioPhy collaborates with various pharmaceutical and life science firms, including innovative companies like Ambrose Healthcare, to identify promising target/drug opportunities and design efficient clinical trials. Their platform boasts an 80% accuracy rate in predicting and guiding clinical trial success across all stages and endpoints, delivering insights that historically took months or years in just a few days.

BioPhy's expanding AI operating system for drug development comprises two key products:

  1. BioPhyRx: A generative AI solution that creates a centralized, user-friendly environment for accessing scientific and regulatory resources. This platform leverages large language models to analyze scientific literature, clinical trials, regulatory guidelines, quality assurance documents, and other industry-specific sources, providing accurate and up-to-date information on demand.
  2. BioLogicAI: A predictive AI engine that offers customized insights to aid life science companies throughout the drug development process. It covers various aspects, including clinical trial endpoint predictability, indication selection, licensing, drug repurposing, asset acquisitions, and divestment. BioLogicAI also assesses the biological feasibility of preclinical assets compared to those in development or already approved by the FDA.

Caroline Kassie, Managing Partner at Metrodora Ventures, highlighted the increasing need for expeditious and effective drug development, especially in the wake of global pandemics and new diseases. She mentioned that a 10% improvement in clinical trial success rates through AI could potentially lead to an additional 250 novel therapies over the next decade. BioPhy is dedicated to turning this prediction into a reality.

BioPhy's reach extends beyond pharmaceutical companies, as it collaborates with organizations in life sciences, U.S. government and intelligence agencies, financial services, and the public sector to navigate the complex landscape of drug development and regulatory compliance. For more information, you can visit their website at biophy.ai.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit